Equities

Emcure Pharmaceuticals Ltd

EMCURE:NSI

Emcure Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,297.35
  • Today's Change-8.60 / -0.66%
  • Shares traded103.36k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jul 26 2024 11:24 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Emcure Pharmaceuticals Ltd is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing and marketing a range of pharmaceutical products across several therapeutic areas. It offers a range of products and services under formulations, biologics, and Active Pharmaceutical Ingredients (APIs). It focuses on various key therapeutic areas, such as gynecology, cardiology, anti-infective, diabetes, biologics, mRNA vaccines, and vitamin, minerals and nutrients. It offers products in both, chronic and acute segments. The Company's subsidiary, Gennova Biopharmaceuticals Limited, is a biotechnology company dedicated to developing, producing, and commercializing bio-therapeutics to address life-threatening diseases across various indications. It has developed two platforms: Mammalian and Microbial. Its key APIs consists of S-Amlodipine, Dydrogesterone, Ferric Carboxymaltose, Ferrous Ascorbate, and Eribulin. It operates approximately 13 manufacturing facilities.

  • Revenue in INR (TTM)66.58bn
  • Net income in INR4.98bn
  • Incorporated1981
  • Employees11.15k
  • Location
    Emcure Pharmaceuticals LtdPlot P-IIIT-BT Park, M.I.D.C., HinjawadiPUNE 411057IndiaIND
  • Phone+91 2 035070033
  • Fax+91 2 039821444
  • Websitehttps://www.emcure.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Granules India Ltd45.06bn4.05bn136.48bn4.12k33.674.2322.283.0316.7216.72185.99133.080.86451.604.6610,932,480.007.7810.6812.4116.1855.1548.838.9911.820.74446.130.28968.96-0.12314.61-21.5411.386.388.45
Eris Lifesciences Ltd20.09bn3.92bn146.08bn3.55k37.305.6525.207.2728.7828.78147.52190.120.3752.375.62--7.4113.4211.2216.8081.0880.2919.7624.960.83455.800.4633--19.2315.392.576.1527.72--
Sanofi India Ltd28.47bn5.49bn153.74bn2.17k28.00--26.105.40238.42238.421,236.19--------13,095,680.00--22.42--30.2157.6855.5219.2921.03--442.82--135.492.920.573-2.859.64-10.3414.73
Concord Biotech Ltd10.17bn3.08bn178.12bn1.38k57.8411.6749.2517.5229.4429.4497.17145.93------7,385,180.00--------77.46--30.30--4.84--0.0063--19.20--28.33------
Astrazeneca Pharma India Ltd12.96bn1.62bn179.32bn940.00111.0225.19101.6213.8464.6064.60518.21284.771.262.849.7913,782,230.0015.6611.7824.4419.6254.1154.6412.4710.271.97141.260.006425.6229.1712.2162.6624.29-10.46--
Piramal Pharma Ltd83.73bn277.60m219.71bn6.72k790.20--28.192.620.21070.210764.75--------12,462,350.00--------64.15--0.3315----7.12----15.39--109.56------
Suven Pharmaceuticals Ltd10.51bn3.00bn236.35bn1.05k78.6411.5366.6022.4811.8111.8141.3480.560.49831.648.589,993,856.0014.2323.1715.1926.2057.3458.8528.5633.219.6447.590.030718.63-21.5622.71-26.9922.41-1.83--
Natco Pharma Ltd.39.99bn13.88bn239.05bn3.98k17.274.0815.185.9877.3077.30222.76326.990.63660.99293.91--22.1012.3325.4614.2582.0876.4734.7225.163.4281.490.0596--47.7213.8194.0916.59-5.76--
Alembic Pharmaceuticals Ltd62.29bn6.16bn239.09bn14.86k38.814.9626.913.8431.3431.34317.00245.120.98651.106.014,192,105.009.7510.7212.9214.2572.4665.989.8912.470.986311.560.096328.2910.199.6280.071.05-15.5914.87
Pfizer Ltd21.93bn5.51bn239.87bn1.70k43.516.6739.0910.94120.52120.52479.40785.950.5331.8612.93--13.4014.2215.6917.7163.8661.7925.1424.054.2737.180.025623.74-9.551.05-11.645.1433.359.24
Laurus Labs Ltd50.54bn1.48bn242.11bn6.01k163.72--43.804.792.742.7493.40--------8,413,434.00--10.13--16.4752.8047.633.0112.83--2.04--13.00-16.5517.07-79.6811.3621.6821.67
Emcure Pharmaceuticals Ltd66.58bn4.98bn245.33bn11.15k49.248.3129.213.6826.3526.35352.11156.120.91971.703.785,973,669.007.297.1413.3013.9361.0259.297.927.810.83195.790.42790.0011.237.14-6.3621.35-5.93--
J B Chemicals and Pharmaceuticals Ltd34.84bn5.53bn292.53bn5.10k54.0110.0142.348.4034.9034.90219.88188.370.92322.505.52--14.6415.7718.0418.8966.0761.1815.8616.061.5617.110.114432.3110.6316.2234.8423.3640.1537.42
Ajanta Pharma Ltd42.09bn8.16bn299.94bn7.84k37.078.4831.527.1364.7964.79334.10283.310.90341.303.655,365,515.0017.5216.6122.4120.4774.6673.2219.3919.312.12--0.009831.2012.4515.4138.8116.10-14.9710.76
IPCA Laboratories Ltd77.07bn5.47bn326.09bn17.34k59.575.1536.794.2321.5821.58303.80249.590.78141.205.644,446,155.005.3710.337.5113.5266.5859.166.8712.251.2813.120.156912.8623.3915.3516.134.2417.9021.67
Gland Pharma Ltd56.65bn7.72bn332.24bn4.59k43.013.8129.745.8746.8946.89343.86529.650.58281.214.12--7.9513.238.9214.5661.6455.8813.6422.922.8537.730.0409--56.2922.61-1.1011.3224.02--
Data as of Jul 26 2024. Currency figures normalised to Emcure Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.